Bibliographie (2530)
COVID-19 and mucormycosis superinfection: the perfect storm.
mercredi, 28 juillet 2021 14:44 Écrit par Zouhair SouissiCOVID-19 and mucormycosis superinfection: the perfect storm – Infection Related: ECMM/ISHAM recommendations for clinical management of COVID -19 associated mucormycosis in low- and middle-income countries. The “Black Fungus” in India: The Emerging Syndemic of COVID-19–Associated Mucormycosis – careful use of antibiotics and corticosteroids and closely monitoring blood glucose levels are some of the strategies suggested […]
The post COVID-19 and mucormycosis superinfection: the perfect storm. appeared first on Links Medicus.
Very rare cases of thrombosis with thrombocytopenia syndrome (TTS) after AstraZeneca vaccine: a global safety database analysis – the estimated rate of TTS after the first dose was 8.1 per million vaccinees; after the second dose, the estimated rate was 2
mercredi, 28 juillet 2021 14:44 Écrit par Zouhair SouissiVery rare thrombosis with thrombocytopenia after second AZD1222 dose: a global safety database analysis – The Lancet Related: WHO Guidance for clinical case management of thrombosis with thrombocytopenia syndrome (TTS) following vaccination to prevent coronavirus disease (COVID-19). AHA/ASA Guidance: Diagnosis and Management of Cerebral Venous Sinus Thrombosis with Vaccine-Induced Thrombotic Thrombocytopenia – “No heparin products […]
The post Very rare cases of thrombosis with thrombocytopenia syndrome (TTS) after AstraZeneca vaccine: a global safety database analysis – the estimated rate of TTS after the first dose was 8.1 per million vaccinees; after the second dose, the estimated rate was 2.3 per million vaccinees. appeared first on Links Medicus.
CoronaVac vaccine: its results are patchy, but the world can’t ignore its usefulness.
mardi, 27 juillet 2021 06:14 Écrit par Zouhair SouissiCoronaVac vaccine: its results are patchy, but the world can’t ignore its usefulness – The Conversation Related: RCT: CoronaVac showed efficacy of 83.5% for preventing symptomatic SARS-CoV-2 infection. Prospective national cohort in Chile showed CoronaVac effectiveness was 65.9% for symptomatic Covid-19, 87.5% for hospitalization, 90.3% for ICU admission, and 86.3% for death. Phase 1/2 RCT: CoronaVac […]
The post CoronaVac vaccine: its results are patchy, but the world can’t ignore its usefulness. appeared first on Links Medicus.
![[Preprint] Test-negative case-control study: Effectiveness of Oxford-AstraZeneca vaccine in order people during SARS-CoV-2 Gamma variant transmission in Brazil – Adjusted effectiveness was 77.9% for symptomatic Covid-19, 87.6% against hospitalization, and](/media/k2/items/cache/0562a0d86b78c2118c302ee89573cf3e_M.jpg)
[Preprint] Test-negative case-control study: Effectiveness of Oxford-AstraZeneca vaccine in order people during SARS-CoV-2 Gamma variant transmission in Brazil – Adjusted effectiveness was 77.9% for symptomatic Covid-19, 87.6% against hospitalization, and
mardi, 27 juillet 2021 06:14 Écrit par Zouhair SouissiEffectiveness of the ChAdOx1 vaccine in the elderly during SARS-CoV-2 Gamma variant transmission in Brazil – medRxiv Commentary on Twitter (thread – click for more) Two new results on vaccine effectiveness of #CoronaVac and #AstraZeneca in #Brazil w/ @otavio_ranzani @juliocroda @datcummings Albert Ko, Jason Andrews and othershttps://t.co/grIg1ydMK6https://t.co/fGmDsi7NdL 1/8 — Matt Hitchings (@MHitchingsEpi) July 23, […]
The post [Preprint] Test-negative case-control study: Effectiveness of Oxford-AstraZeneca vaccine in order people during SARS-CoV-2 Gamma variant transmission in Brazil – Adjusted effectiveness was 77.9% for symptomatic Covid-19, 87.6% against hospitalization, and 93.6% against death. appeared first on Links Medicus.
![[Preprint] Test-negative case-control study: Effectiveness of CoronaVac vaccine in order people during SARS-CoV-2 Gamma variant transmission in Brazil – Adjusted vaccine effectiveness was 41.6% for symptomatic Covid-19, 59.0% against hospitalizations and](/media/k2/items/cache/6ce8174e82984e94a7a98889b7c17e32_M.jpg)
[Preprint] Test-negative case-control study: Effectiveness of CoronaVac vaccine in order people during SARS-CoV-2 Gamma variant transmission in Brazil – Adjusted vaccine effectiveness was 41.6% for symptomatic Covid-19, 59.0% against hospitalizations and
mardi, 27 juillet 2021 06:14 Écrit par Zouhair SouissiEffectiveness of the CoronaVac vaccine in the elderly population during a Gamma variant-associated epidemic of COVID-19 in Brazil: A test-negative case-control study – medRxiv Commentary on Twitter (thread – click for more) Two new results on vaccine effectiveness of #CoronaVac and #AstraZeneca in #Brazil w/ @otavio_ranzani @juliocroda @datcummings Albert Ko, Jason Andrews and othershttps://t.co/grIg1ydMK6https://t.co/fGmDsi7NdL […]
The post [Preprint] Test-negative case-control study: Effectiveness of CoronaVac vaccine in order people during SARS-CoV-2 Gamma variant transmission in Brazil – Adjusted vaccine effectiveness was 41.6% for symptomatic Covid-19, 59.0% against hospitalizations and 71.4% against deaths. appeared first on Links Medicus.
Another study shows increased immune response with heterologous Oxford-AstraZeneca/mRNA vaccination.
mardi, 27 juillet 2021 06:14 Écrit par Zouhair SouissiImmunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination – Nature Medicine Commentary: A ‘mix and match’ approach to SARS-CoV-2 vaccination – Nature Medicine Related: WHO warns against mixing and matching COVID vaccines. Germany issues world’s strongest recommendation for mixing Covid-19 vaccines. Heterologous Oxford–AstraZeneca and Moderna Vaccination induce increased levels of neutralizing antibody compared to 2 […]
The post Another study shows increased immune response with heterologous Oxford-AstraZeneca/mRNA vaccination. appeared first on Links Medicus.
Safety evaluation of the second dose of mRNA COVID-19 vaccines in patients with immediate reactions to the first dose.
mardi, 27 juillet 2021 06:14 Écrit par Zouhair SouissiSafety Evaluation of the Second Dose of Messenger RNA COVID-19 Vaccines in Patients With Immediate Reactions to the First Dose – JAMA Internal Medicine Commentaries: Second COVID-19 mRNA vaccine dose found safe following allergic reactions to first dose – Massachusetts General Hospital No anaphylaxis after second dose of mRNA COVID vaccine, study finds – CIDRAP […]
The post Safety evaluation of the second dose of mRNA COVID-19 vaccines in patients with immediate reactions to the first dose. appeared first on Links Medicus.
Review: Long covid—mechanisms, risk factors, and management.
mardi, 27 juillet 2021 06:14 Écrit par Zouhair SouissiLong covid—mechanisms, risk factors, and management – The BMJ Commentary on Twitter Great review in @bmj_latest of what we know – and all that we don't – about Long Covid. Including this graphic of different ways it can manifest. article here https://t.co/zsqNVNVEo8 https://t.co/V4C5aJbpg0 pic.twitter.com/5XU1W557wQ — Prof. Christina Pagel (@chrischirp) July 26, 2021
The post Review: Long covid—mechanisms, risk factors, and management. appeared first on Links Medicus.
![[Preprint] Covid-19: Longer interval between Covid-19 Pfizer vaccine doses boosts immunity.](/media/k2/items/cache/53af0161bdcf4c892c691e5fb176523b_S.jpg)
[Preprint] Covid-19: Longer interval between Covid-19 Pfizer vaccine doses boosts immunity.
mardi, 27 juillet 2021 06:14 Écrit par Zouhair SouissiNews release: Longer interval between Covid-19 Pfizer vaccine doses boosts immunity – Newcastle University Original Study (preprint): Sustained T cell immunity, protection and boosting using extended dosing intervals of BNT162b2 mRNA vaccine Commentaries: Commentary: Covid-19: Longer interval between Pfizer doses results in higher antibody levels, research finds – BMJ Expert reaction to preprint from PITCH […]
The post [Preprint] Covid-19: Longer interval between Covid-19 Pfizer vaccine doses boosts immunity. appeared first on Links Medicus.
Study: Among kidney transplant recipients who did not respond after 2 doses, a third dose of an mRNA-1273 vaccine induced a serologic response in 49% of patients.
lundi, 26 juillet 2021 09:29 Écrit par Zouhair SouissiAntibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses – JAMA Commentary: Case Mounts for COVID Vaccine Boosters in Kidney Transplant Recipients – MedPage Today (free registration required) Related: Case series: Safety and immunogenicity of a third dose of SARS-CoV-2 vaccine in […]
The post Study: Among kidney transplant recipients who did not respond after 2 doses, a third dose of an mRNA-1273 vaccine induced a serologic response in 49% of patients. appeared first on Links Medicus.
![[Preprint] RCT: In patients with COVID-19 and severe hypoxia, dexamethasone 12 mg did NOT result in statistically significant improved outcomes compared to dexamethasone 6 mg – “Mortality at 28 days was 27.1% and 32.3% in patients assigned to 12 mg and 6](/media/k2/items/cache/306600c868fe6b67afe34e9f7a9f98b7_XS.jpg)